Vitamin A metabolism is impaired in human ovarian cancer

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 637-645

  Williams, Stephen J ^a   Cvetkovic, Dusica ^a   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cancer; Cellular retinol binding protein 1; Ovarian; Vitamin A

Indexed keywords

CELLULAR RETINOL BINDING PROTEIN 1; CRABP1 PROTEIN; CRABP2 PROTEIN; RALDH1 PROTEIN; RALDH2 PROTEIN; RETINAL; RETINAL DEHYDROGENASE; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; RETINOL; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENETIC RISK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; VITAMIN METABOLISM;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; RETINALDEHYDE; RETINOL-BINDING PROTEINS, CELLULAR; TRETINOIN; VITAMIN A;

EID: 60449113391     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.015     Document Type: Article

References (59)

1. Zhang D., Holmes W.F., Wu S., Soprano D.R., and Soprano K.J. Retinoids and ovarian cancer. J. Cell. Physiol. 185 1 (2000, Oct) 1-20
2. Degos L., and Parkinson D. Retinoids in oncology (1995), Springer-Verlag, Berlin
3. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 10 9 (1996, Jul) 1031-1039
4. Fontana J.A., and Rishi A.K. Classical and novel retinoids: their targets in cancer therapy. Leukemia 16 4 (2002, Apr) 463-472
5. Mira Y.L.R., Zheng W.L., Kuppumbatti Y.S., Rexer B., Jing Y., and Ong D.E. Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J. Cell. Physiol. 185 2 (2000, Nov) 302-309
6. Kim H., Lapointe J., Kaygusuz G., Ong D.E., Li C., van de Rijn M., et al. The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res 65 18 (2005, Sep 15) 8118-8124
7. Pasquali D., Thaller C., and Eichele G. Abnormal level of retinoic acid in prostate cancer tissues. J. Clin. Endocrinol. Metab. 81 6 (1996, Jun) 2186-2191
8. Napoli J.L. A gene knockout corroborates the integral function of cellular retinol-binding protein in retinoid metabolism. Nutr. Rev. 58 8 (2000, Aug) 230-236
9. Lotan R. A crucial role for cellular retinol-binding protein I in retinoid signaling. J. Natl. Cancer Inst. 97 1 (2005, Jan 5) 3-4
10. Napoli J.L. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim. Biophys. Acta 1440 2-3 (1999, Sep 22) 139-162
11. Jing Y., Zhang J., Bleiweiss I.J., Waxman S., Zelent A., and Mira Y.L.R. Defective expression of cellular retinol binding protein type I and retinoic acid receptors alpha2, beta2, and gamma2 in human breast cancer cells. FASEB J. 10 9 (1996, Jul) 1064-1070
12. Kuppumbatti Y.S., Bleiweiss I.J., Mandeli J.P., Waxman S., and Mira Y.L.R. Cellular retinol-binding protein expression and breast cancer. J Natl. Cancer Inst. 92 6 (2000, Mar 15) 475-480
13. Kwong J., Lo K.W., Chow L.S., To K.F., Choy K.W., Chan F.L., et al. Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. Neoplasia 7 1 (2005, Jan) 67-74
14. Yamashita K., Upadhyay S., Osada M., Hoque M.O., Xiao Y., Mori M., et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2 6 (2002, Dec) 485-495
15. Luo L., Chen W.D., and Pretlow T.P. CpG island methylation in aberrant crypt foci and cancers from the same patients. Int. J. Cancer 115 5 (2005, Jul 10) 747-751
16. Schmitt-Graff A., Ertelt V., Allgaier H.P., Koelble K., Olschewski M., Nitschke R., et al. Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with beta-catenin, Ki-67 index, and patient survival. Hepatology 38 2 (2003, Aug) 470-480
17. Jeronimo C., Henrique R., Oliveira J., Lobo F., Pais I., Teixeira M.R., et al. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. J. Clin. Pathol. 57 8 (2004, Aug) 872-876
18. Morris E.J., Dreixler J.C., Cheng K.Y., Wilson P.M., Gin R.M., and Geller H.M. Optimization of single-cell gel electrophoresis (SCGE) for quantitative analysis of neuronal DNA damage. Biotechniques 26 2 (1999, Feb) 282-283 6-9
19. Lehmann S., Paul C., and Torma H. The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity. Leuk. Lymphoma 43 4 (2002, Apr) 851-858
20. Bistulfi G., Pozzi S., Ren M., Rossetti S., and Sacchi N. A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. Cancer Res. 66 21 (2006, Nov 1) 10308-10314
21. Guo X., Nanus D.M., Ruiz A., Rando R.R., Bok D., and Gudas L.J. Reduced levels of retinyl esters and vitamin A in human renal cancers. Cancer Res. 61 6 (2001, Mar 15) 2774-2781
22. Bertone E.R., Hankinson S.E., Newcomb P.A., Rosner B., Willet W.C., Stampfer M.J., et al. A population-based case-control study of carotenoid and vitamin A intake and ovarian cancer (United States). Cancer Causes Control 12 1 (2001, Jan) 83-90
23. Fairfield K.M., Hankinson S.E., Rosner B.A., Hunter D.J., Colditz G.A., and Willett W.C. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 92 9 (2001, Nov 1) 2318-2326
24. Cramer D.W., Kuper H., Harlow B.L., and Titus-Ernstoff L. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. Int. J. Cancer 94 1 (2001, Oct 1) 128-134
25. Das N.P., Ma C.W., and Salmon Y.M. The relationship of serum vitamin A, cholesterol, and triglycerides to the incidence of ovarian cancer. Biochem. Med. Metab. Biol. 37 2 (1987, Apr) 213-219
26. Heinonen P.K., Kuoppala T., Koskinen T., and Punnonen R. Serum vitamins A and E and carotene in patients with gynecologic cancer. Arch. Gynecol. Obstet. 241 3 (1987) 151-156
27. Veronesi U., De Palo G., Marubini E., Costa A., Formelli F., Mariani L., et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91 21 (1999, Nov 3) 1847-1856
28. De Palo G., Veronesi U., Camerini T., Formelli F., Mascotti G., Boni C., et al. Can fenretinide protect women against ovarian cancer?. J. Natl. Cancer Inst. 87 2 (1995, Jan 18) 146-147
29. Godwin A.K., Testa J.R., Handel L.M., Liu Z., Vanderveer L.A., Tracey P.A., et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J. Natl. Cancer Inst. 84 8 (1992, Apr 15) 592-601
30. Testa J.R., Getts L.A., Salazar H., Liu Z., Handel L.M., Godwin A.K., et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 54 10 (1994, May 15) 2778-2784
31. Roberts D., Williams S.J., Cvetkovic D., Weinstein J.K., Godwin A.K., Johnson S.W., et al. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol. 21 1 (2002, Jan) 11-19
32. Cvetkovic D., Williams S.J., and Hamilton T.C. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin. Cancer Res. 9 3 (2003, Mar) 1013-1020
33. Eriksson U., and Gustafsson A.L. Immunohistochemistry for CRBPs and CRABPs. Methods Mol. Biol. 89 (1998) 57-66
34. Busch C., Sakena P., Funa K., Nordlinder H., and Eriksson U. Tissue distribution of cellular retinol-binding protein and cellular retinoic acid-binding protein: use of monospecific antibodies for immunohistochemistry and cRNA for in situ localization of mRNA. Methods Enzymol. 189 (1990) 315-324
35. Kruk P.A., Godwin A.K., Hamilton T.C., and Auersperg N. Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol. Oncol. 73 2 (1999, May) 229-236
36. Auersperg N., Maines-Bandiera S., Booth J.H., Lynch H.T., Godwin A.K., and Hamilton T.C. Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. Am. J. Obstet. Gynecol. 173 2 (1995, Aug) 558-565
37. Maines-Bandiera S.L., Kruk P.A., and Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am. J. Obstet. Gynecol. 167 3 (1992, Sep) 729-735
38. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43 11 (1983, Nov) 5379-5389
39. Shridhar V., Lee J., Pandita A., Iturria S., Avula R., Staub J., et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61 15 (2001, Aug 1) 5895-5904
40. Uchida D., Kawamata H., Nakashiro K., Omotehara F., Hino S., Hoque M.O., et al. Low-dose retinoic acid enhances in vitro invasiveness of human oral squamous-cell-carcinoma cell lines. Br. J. Cancer 85 1 (2001, Jul 6) 122-128
41. Rexer B.N., Zheng W.L., and Ong D.E. Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells. Cancer Res. 61 19 (2001 (Oct 1)) 7065-7070
42. Sakhi A.K., Gundersen T.E., Ulven S.M., Blomhoff R., and Lundanes E. Quantitative determination of endogenous retinoids in mouse embryos by high-performance liquid chromatography with on-line solid-phase extraction, column switching and electrochemical detection. J. Chromatogr. A 828 1-2 (1998, Dec 18) 451-460
43. Rogers E.J., Sabrah T., Hebert J.R., Ausman L.M., Hegsted D.M., and Nicolosi R.J. A comparison of serum retinol concentration between human and different species of normo and hypercholesterolemic nonhuman primates fed semi-purified diets with defined amounts of vitamin A. Comp. Biochem. Physiol. Comp. Physiol. 106 4 (1993, Dec) 749-754
44. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976, May 7) 248-254
45. Schlosshauer P.W., Cohen C.J., Penault-Llorca F., Miranda C.R., Bignon Y.J., Dauplat J., et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 98 12 (2003, Dec 15) 2599-2606
46. Colgan T.J., Murphy J., Cole D.E., Narod S., and Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 25 10 (2001, Oct) 1283-1289
47. Lu K.H., Garber J.E., Cramer D.W., Welch W.R., Niloff J., Schrag D., et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol. 18 14 (2000, Jul) 2728-2732
48. Deligdisch L., Gil J., Kerner H., Wu H.S., Beck D., and Gershoni-Baruch R. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations. Cancer 86 8 (1999, Oct 15) 1544-1550
49. Salazar H., Godwin A.K., Daly M.B., Laub P.B., Hogan W.M., Rosenblum N., et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. 88 24 (1996, Dec 18) 1810-1820
50. Sherman M.E., Lee J.S., Burks R.T., Struewing J.P., Kurman R.J., and Hartge P. Histopathologic features of ovaries at increased risk for carcinoma. a case-control analysis. Int. J. Gynecol. Pathol. 18 2 (1999, Apr) 151-157
51. Mittal K.R., Zeleniuch-Jacquotte A., Cooper J.L., and Demopoulos R.I. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int. J. Gynecol. Pathol. 12 1 (1993, Jan) 59-63
52. Hayden L.J., Hawk S.N., Sih T.R., and Satre M.A. Metabolic conversion of retinol to retinoic acid mediates the biological responsiveness of human mammary epithelial cells to retinol. J. Cell. Physiol. 186 3 (2001, Mar) 437-447
53. Hayden L.J., and Satre M.A. Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells. Breast Cancer Res. Treat. 72 2 (2002, Mar) 95-105
54. Zhang D., Vuocolo S., Masciullo V., Sava T., Giordano A., Soprano D.R., et al. Cell cycle genes as targets of retinoid induced ovarian tumor cell growth suppression. Oncogene 20 55 (2001, Nov 29) 7935-7944
55. Kaiser P.C., Korner M., Kappeler A., and Aebi S. Retinoid receptors in ovarian cancer: expression and prognosis. Ann. Oncol. 16 9 (2005, Sep) 1477-1487
56. Holmes W.F., Soprano D.R., and Soprano K.J. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J. Biol. Chem. 277 47 (2002, Nov 22) 45408-45419
57. Ross S.A., McCaffery P.J., Drager U.C., and De Luca L.M. Retinoids in embryonal development. Physiol. Rev. 80 3 (2000, Jul) 1021-1054
58. Hansen L.A., Sigman C.C., Andreola F., Ross S.A., Kelloff G.J., and De Luca L.M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21 7 (2000, Jul) 1271-1279
59. Wu S., Zhang Z.P., Zhang D., Soprano D.R., and Soprano K.J. Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all-trans-retinoic acid. Exp. Cell Res. 237 1 (1997, Nov 25) 118-126